Rat Kilham Virus IgG ELISA Kit

Name: Rat Kilham Virus IgG ELISA Kit
SKU: DEIAJX006
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum and other biological fluids

Species Reactivity

Rat

Intended Use

The Rat anti-Kilham Rat Virus IgG ELISA Kit is an immunoassay suitable for detecting and quantifying IgG antibody activity specific for KRV major capsid protein (VP2) antigen in serum or plasma. Other biological fluids, including tissue culture medium, may be validated for use.

Storage

2-8°C until the expiration date printed on the box label.

Precision

Samples and Controls were assayed in duplicate in 5 separate runs, to provide a measure of between-assay reproducibility.
The data are represented using the value of the Sensitivity Control in each assay to calculate a Threshold Index for each control and samples.

The coefficient of variation (%CV) shows the reproducibility of the assay for measuring one antibody activity (sample or control) relative to another antibody activity (Sensitivity Control). Variation increases in the threshold region; for this reason, consider running additional tests for borderline samples.

Sensitivity

The KRV antigen coating level, HRP conjugate concentration, and Low NSB Sample Diluent are optimized to differentiate antiKRV IgG from background (non-antibody) signal with rat serum samples diluted 1:100.

General Description

Three serogroups of parvoviruses affect rats: PV (including Kilham rat virus, KRV), RPV and H-1 (Toolans). Parvoviruses are typically linear, non-segmented ssDNA viruses with an average genome size of 5Kb, and target replicating tissue causing cell and tissue destruction. This explains why RV, in its active stage, will interfere with the formation of offspring, causing small litters, stillborns, or the resorption of litters.The viral capsid of a parvovirus is made up of two or three proteins, known as VP1-3, that form an icosahedral structure; VP2 is highly immunogenic.
KRV infection may be diagnosed by ELISA, measuring rapidly rising antibody titers (8-12 days after infection) to KRV antigen. Animals infected with KRV are not suitable for animal research; in addition to lower growth rates, KRV may predispose to secondary bacterial infection, cause infertility, and death in susceptible strains. Besides infecting animals, KRV may also contaminate cell lines, transplantable tumors and other biological products; these should be tested by rat antibody production (RAP), using ELISA to detect anti- KRV after immunization.
RecombiVirus ELISAs are 2nd generation immunoassays using highly purified, recombinant and antigenic proteins of animal viruses. The Creative Diagnostics Rat Anti-KRV IgG ELISA is designed with high sensitivity for the detection of antibodies during KRV infection.

Citations

Have you cited DEIAJX006 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Q & A

Ask a Question

Q: Does Rat Kilham Virus IgG ELISA Kit (DEIAJX006) react with rat H-1 parvovirus in ELISA? sample: Rat parvovirus H-1 VR-356 from ATCC.

A: The kit detects antibodies to KRV VP2, it does not react with antigens. Cross-reactivity has not been assessed with other viruses.

Customer Reviews

References

Parvovirus-Induced Transient Aplastic Crisis in a Patient With Newly Diagnosed Hereditary Spherocytosis

CUREUS

Authors: Nandu, Nitish Singh; Hafzah, Husam; Patel, Charmi

Abstract

Parvovirus B19 infections are prevalent in children and commonly present as slapped cheek fever, also known as the fifth disease. They are seen frequently in daycares and professions that require close contact with children. The most common presentation is a rash that is prominent on the cheeks; less common symptoms include painful or swollen joints (polyarthopathy syndrome). The infection is self-limited and resolves within one to two weeks. The virus has an affinity to the red blood cell (RBC) precursors and can rarely cause temporary cessation of the bone marrow's RBC production, leading to aplastic anemia. This is especially of significance in patients predisposed to increased RBC destruction, such as hereditary spherocytosis, sickle cell anemia, and other morphological abnormalities of the RBC. The overlapping arrest of RBC production and excessive destruction leads to a transient aplastic crisis (TAC), leading to severe life-threatening anemia, requiring blood urgent blood transfusions. There have been many studies reporting the incidence of TAC in patients with sickle cell crisis. Only a few cases have been reported in patients with hereditary spherocytosis.

Field evaluation of the safety and compatibility of a combined vaccine against porcine parvovirus 1 and porcine reproductive and respiratory syndrome virus in breeding animals

PORCINE HEALTH MANAGEMENT

Authors: Garcia-Morante, Beatriz; Noguera, Marta; Kraft, Christian; Bridger, Philip

Abstract

Background Porcine reproductive and respiratory syndrome virus (PRRSV) and porcine parvovirus 1 (PPV1) are two common causes of reproductive failure. ReproCyc (R) ParvoFLEX is a novel subunit vaccine based on the protective viral protein (VP) 2 of PPV1 that has been recently licensed in the European (EU) market, whereas ReproCyc (R) PRRS EU is a porcine reproductive and respiratory syndrome (PRRS) modified live virus (MLV) vaccine authorized in 2015. The present work sought to evaluate the safety and compatibility of the combined administration of the abovementioned vaccines in target animals under the context of a field PRRSV (experiment A) and PPV1 (experiment B) infection. To achieve this objective, safety and lack of vaccines' antigen interference were established according to the absence of significant differences between the combined vaccinated animals (PPRSV+PPV1) and the single vaccinated animals against PRRSV or PPV1. In both experiments, gilts and sows were evaluated for local and systemic reactions after vaccination as well as for reproductive and productive performance. In addition, tissues from abortions, mummified fetuses and stillborn piglets were analyzed for the presence of PRRSV and PPV1. Lastly, serology and viremia were determined in experiment B. Results No relevant differences in terms of safety, reproductive and productive performance between the single vaccinated and the combined vaccinated animals in either experiment were observed. Conclusions ReproCyc (R) PRRS EU mixed with ReproCyc (R) ParvoFLEX can be used as a safe method of protection against the detrimental effects of PRRSV and PPV1 infections in breeding female pigs in one single injection. The present results also open up opportunities to tackle reproductive problems as a whole by combining control programs against swine reproductive pathogens.